DEC 06, 2016 08:00 AM PST

Pre-emptive genotyping for pharmacogenomic risk - establishing a benchmark

SPONSORED BY: Affymetrix, Affymetrix
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Pediatrics, Medicine and Physiology, Chief - Section of Genomic Pediatrics, Department of Pediatrics, Medical College of Wisconsin
    Biography
      Ulrich Broeckel, MD is a Professor of Pediatrics, Medicine and Physiology and the Chief of the Section of Genomic Pediatrics, at the Medical College of Wisconsin. Dr. Broeckel received his MD from the University of Heidelberg, Germany. He continued his training in internal medicine and cardiology. His research focuses on genetics of cardiovascular diseases, pediatric genetics and pharmacogenetics. His lab uses induced pluripotent stem cells to study the functional effect of genome variation. He is also the technical director of a CAP/CLIA certified clinical genetic testing laboratory.

    Abstract:

    DATE: December 6, 2016
    TIME: 8:00am PT, 11:00am ET

    Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in health care. In the US alone, an estimated two million serious ADRs occur annually, causing over 100,000 deaths per year. Based on these estimates, ADRs are the 4th leading cause of death ahead of pulmonary disease, diabetes, AIDS, and pneumonia. The percentage of hospital admissions due to ADRs in some countries exceeds 10%. 

    Due to the magnitude of this problem healthcare organizations and pharmaceutical companies worldwide are developing major initiatives to reduce the cost and impact of ADRs. Pre-emptive pharmacogenomic genotyping is a pivotal new approach using genetic data to gain valuable insights into metabolic status to better understand the cause of adverse events. 

    Ulrich Broeckel, MD and Chief, Section of Genomic Pediatrics at the Medical College of Wisconsin, is a leader in pharmacogenomics research and will share his experience in establishing a new benchmark for pre-emptive genotyping for pharmacogenomics.

    During this session you will learn:

    • How translational clinical researchers gain valuable insight into an individual’s ability to process drugs known to be actionable and where high, moderate, low, preliminary and unknown evidence exists
    • Why genotyping of highly predictive markers in genes including GSTM1, CYP1A2, CYP2D6, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C8 that are in highly homologous regions is important 
    • How copy number variation (CNV) analysis for important ADME genes is integrated into the system 

    For Research Use Only. Not for use in diagnostic procedures.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...